VTP-200
Low-grade HPV-related Cervical Lesions
Phase 1b/2Active
Key Facts
Indication
Low-grade HPV-related Cervical Lesions
Phase
Phase 1b/2
Status
Active
Company
About Barinthus Biotherapeutics
Barinthus Biotherapeutics is a UK-based, NASDAQ-listed biotech (BRNS) focused on developing novel immunotherapies for immunology and inflammatory (I&I) indications. The company's strategy centers on its two core technology platforms—the proprietary SNAP nanoparticle system and the established ChAdOx/MVA viral vectors—to 'guide' antigen-specific T cell responses. Recent clinical achievements include positive Phase 1b/2a data for its chronic hepatitis B candidate, VTP-300, showing sustained antigen reduction, and a favorable tolerability profile for its HPV candidate, VTP-200. Barinthus aims to translate its strong academic heritage into differentiated clinical assets in areas of high unmet need.
View full company profile